此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)

2017年2月14日 更新者：Merck Sharp & Dohme LLC

A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA™, in Treatment-Naïve HIV Infected Patients

A study to evaluate the safety, tolerability and efficacy of once daily Raltegravir compared to twice daily raltegravir when each is given in combination with TRUVADA™ in treatment-naïve human immunodeficiency virus (HIV)-infected patients.

研究概览

地位

终止

条件

干预/治疗

详细说明

Following the 96-week double-blind study period (MK0518-071)(NCT00745823), subjects may enroll in an extension study (MK0518-071-10)(NCT00745823). From weeks 96 to 120, subjects' treatment assignments will remain as in the base study.

From week 120 to 240, all subjects will receive open-label raltegravir (800 mg, once daily) in combination with TRUVADA™.

研究类型

介入性

注册 (实际的)

775

阶段

  • 第三阶段

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patient is male or female 18 years of age or older
  • Patient is HIV positive
  • Patient is naïve to antiretroviral therapy (ART) or has received less than 7 days total of any ART

Extension Study:

  • The planned extension study did not take place as the study was terminated after the Week 48 analysis.

Exclusion Criteria:

  • Patient is a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence
  • Patient has documented resistance to tenofovir or emtricitabine
  • Patient is currently participating or has participated in a study with an investigational compound or device within 45 days of signing informed consent
  • Patient is pregnant or breastfeeding, or expecting to conceive

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：双倍的

武器和干预

参与者组/臂
干预/治疗
有源比较器：Raltegravir 400 mg b.i.d.
药品：Comparator: Raltegravir 400 mg b.i.d.
Raltegravir 400 mg tablet by mouth (PO) twice daily (b.i.d.) + two raltegravir placebo tablets + one tablet of TRUVADA™ once daily (q.d.)
其他名称：
  • 中心™
药品：TRUVADA™
One tablet TRUVADA™ q.d. (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate)
实验性的：Raltegravir 800 mg q.d.
药品：TRUVADA™
One tablet TRUVADA™ q.d. (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate)
药品：Experimental: Raltegravir 800 mg q.d.
Raltegravir 800 mg tablet PO q.d. + two raltegravir placebo tablets + one tablet TRUVADA™ q.d.
其他名称：
  • 中心™

研究衡量的是什么？

主要结果指标

结果测量
大体时间
Number of Participants With HIV Ribonucleic Acid (RNA) <50 Copies/mL at 48 Weeks
大体时间：Week 48
Week 48
Number of Participants With One or More Adverse Events at 48 Weeks
大体时间：Week 48
Week 48
Number of Participants Who Discontinued Due to an Adverse Event at 48 Weeks
大体时间：Week 48
Week 48

次要结果测量

结果测量
措施说明
大体时间
Number of Participants With HIV Ribonucleic Acid (RNA) <400 Copies/mL at 48 Weeks
大体时间：48 weeks
48 weeks
Mean Change From Baseline to Week 48 in CD4 Cell Count
大体时间：Baseline and Week 48
Baseline and Week 48
Number of Participants With HIV RNA <50 Copies/mL at 96 Weeks
大体时间：Week 96
As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.
Week 96
Number of Participants With HIV RNA <400 Copies/mL at 96 Weeks
大体时间：Week 96
As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.
Week 96
Mean Change From Baseline to Week 96 in CD4 Cell Count
大体时间：Baseline and Week 96
As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.
Baseline and Week 96
Number of Participants With One or More Adverse Events at 96 Weeks
大体时间：Week 96
As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.
Week 96
Number of Participants Who Discontinued Due to an Adverse Event at 96 Weeks
大体时间：Week 96
As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.
Week 96

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Merck Sharp & Dohme LLC

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2008年9月1日

初级完成 (实际的)

2010年10月1日

研究完成 (实际的)

2011年5月1日

研究注册日期

首次提交

2008年9月2日

首先提交符合 QC 标准的

2008年9月2日

首次发布 (估计)

2008年9月3日

研究记录更新

最后更新发布 (实际的)

2017年3月21日

上次提交的符合 QC 标准的更新

2017年2月14日

最后验证

2017年2月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • 0518-071
  • 2008_543 (其他标识符：Merck Registration Number)
  • CTRI/2009/091/000145 (注册表标识符：CTRI)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

是的

IPD 计划说明

http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅